For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- 7 Diseases to Gain Importance in Next 10 Years: JHSF Report
May 23, 2011
- Iberica HD to Expand Clinical Pharmacology Facilities in the US
May 23, 2011
- NBI Stresses Good Cost-effectiveness of Prazaxa
May 23, 2011
- Fuji Yakuhin: Drugstore Division Sales Up 1.4% in FY2010
May 23, 2011
- New Data Confirms Levemir's Efficacy for Type 1 Diabetes in Children Aged 2-5: Novo Nordisk
May 23, 2011
- Takeda Aims for Recovery through Shift toward New Products
May 23, 2011
- Prescriptions Filled by Growell HD Up 40%
May 23, 2011
- 39% of Hospitals Return to Black
May 23, 2011
- Takeda's Patents Cited in Largest Number of Notices of Reasons for Patent Refusal
May 23, 2011
- Teva to Buy 57% Stake in Taiyo for ¥37 Bil.
May 23, 2011
- Domestic Sales of New Drugs Contribute to Growth: Otsuka HD
May 23, 2011
- Legal Prescription Receipt Rate Exceeds 65%: JPA
May 16, 2011
- Production to Resume at Takahagi Tech Center in Oct.: Astellas
May 16, 2011
- Tramcet Combination Tab Approved for Relief of Chronic Pain: Janssen
May 16, 2011
- Industry Concerned About Possibility of Consecutive NHI Price Revisions
May 16, 2011
- Takara Bio Aims for Sales of ¥22,700 Mil. in FY2013
May 16, 2011
- Suprane Approved for Inhalation Anesthesia: Baxter
May 16, 2011
- Taiyo Reportedly Seeking Strategic Alliance with Teva
May 16, 2011
- Alfresa HD Revises Profit Forecasts Downward Due to Losses Caused by Quake
May 16, 2011
- Genzyme's Thymoglobulin Obtains Additional Indication
May 16, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…